InvestorsHub Logo
Followers 4
Posts 171
Boards Moderated 0
Alias Born 03/02/2015

Re: None

Wednesday, 05/05/2021 8:48:47 AM

Wednesday, May 05, 2021 8:48:47 AM

Post# of 863
$OTLK President, CEO and CFO Lawrence A. Kenyon was featured in a video interview discussing the pivotal Phase 3 NORSE TWO trial and the potential for ONS-5010 ophthalmic bevacizumab to treat #wetAMD.

https://www.proactiveinvestors.com/companies/news/946333/outlook-therapeutics--almost-complete--with-pivotal-phase-3-norse-two-trial-to-treat-wet-amd-946333.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent OTLK News